Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer

Silvana Carr, Kim J. Allison, Lee Ann Van De Velde, Kelly Zhang, Elizabeth Y. English, Amy Iverson, Najat C. Daw, Scott Howard, Fariba Navid, Carlos Rodriguez-Galindo, Jie Yang, Elisabeth E. Adderson, Jonathan Mccullers, Patricia M. Flynn

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

(See the editorial commentary by Halasa, on pages 1471-4.)Background.The safety and immunogenicity of live, attenuated influenza vaccine (LAIV) has not been compared to that of the standard trivalent inactivated vaccine (TIV) in children with cancer.Methods.Randomized study of LAIV versus TIV in children with cancer, age 2-21 years, vaccinated according to recommendations based on age and prior vaccination. Data on reactogenicity and other adverse events and blood and nasal swab samples were obtained following vaccination.Results.Fifty- five eligible subjects (mean age, 10.4 years) received vaccine (28 LAIV/27 TIV). Both vaccines were well tolerated. Rhinorrhea reported within 10 days of vaccination was similar in both groups (36% LAIV vs 33% TIV, P >. 999). Ten LAIV recipients shed virus; the latest viral shedding was detected 7 days after vaccination. Immunogenicity data were available for 52 subjects, or 26 in each group. TIV induced significantly higher postvaccination geometric mean titers against influenza A viruses (P <. 001), greater seroprotection against influenza A/H1N1 (P =. 01), and greater seroconversion against A/H3N2 (P =. 004), compared with LAIV. No differences after vaccination were observed against influenza B viruses.Conclusions.As expected, serum antibody response against influenza A strains were greater with TIV than with LAIV in children with cancer. Both vaccines were well tolerated, and prolonged viral shedding after LAIV was not detected.

Original languageEnglish (US)
Pages (from-to)1475-1482
Number of pages8
JournalJournal of Infectious Diseases
Volume204
Issue number10
DOIs
StatePublished - Nov 15 2011

Fingerprint

Attenuated Vaccines
Inactivated Vaccines
Influenza Vaccines
Safety
Vaccination
Neoplasms
Virus Shedding
Human Influenza
Vaccines
Influenza B virus
Influenza A virus
Nose
Antibody Formation
Viruses

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Carr, S., Allison, K. J., Van De Velde, L. A., Zhang, K., English, E. Y., Iverson, A., ... Flynn, P. M. (2011). Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. Journal of Infectious Diseases, 204(10), 1475-1482. https://doi.org/10.1093/infdis/jir561

Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. / Carr, Silvana; Allison, Kim J.; Van De Velde, Lee Ann; Zhang, Kelly; English, Elizabeth Y.; Iverson, Amy; Daw, Najat C.; Howard, Scott; Navid, Fariba; Rodriguez-Galindo, Carlos; Yang, Jie; Adderson, Elisabeth E.; Mccullers, Jonathan; Flynn, Patricia M.

In: Journal of Infectious Diseases, Vol. 204, No. 10, 15.11.2011, p. 1475-1482.

Research output: Contribution to journalArticle

Carr, S, Allison, KJ, Van De Velde, LA, Zhang, K, English, EY, Iverson, A, Daw, NC, Howard, S, Navid, F, Rodriguez-Galindo, C, Yang, J, Adderson, EE, Mccullers, J & Flynn, PM 2011, 'Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer', Journal of Infectious Diseases, vol. 204, no. 10, pp. 1475-1482. https://doi.org/10.1093/infdis/jir561
Carr, Silvana ; Allison, Kim J. ; Van De Velde, Lee Ann ; Zhang, Kelly ; English, Elizabeth Y. ; Iverson, Amy ; Daw, Najat C. ; Howard, Scott ; Navid, Fariba ; Rodriguez-Galindo, Carlos ; Yang, Jie ; Adderson, Elisabeth E. ; Mccullers, Jonathan ; Flynn, Patricia M. / Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. In: Journal of Infectious Diseases. 2011 ; Vol. 204, No. 10. pp. 1475-1482.
@article{0267f57490834a1cbe83d1f599764282,
title = "Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer",
abstract = "(See the editorial commentary by Halasa, on pages 1471-4.)Background.The safety and immunogenicity of live, attenuated influenza vaccine (LAIV) has not been compared to that of the standard trivalent inactivated vaccine (TIV) in children with cancer.Methods.Randomized study of LAIV versus TIV in children with cancer, age 2-21 years, vaccinated according to recommendations based on age and prior vaccination. Data on reactogenicity and other adverse events and blood and nasal swab samples were obtained following vaccination.Results.Fifty- five eligible subjects (mean age, 10.4 years) received vaccine (28 LAIV/27 TIV). Both vaccines were well tolerated. Rhinorrhea reported within 10 days of vaccination was similar in both groups (36{\%} LAIV vs 33{\%} TIV, P >. 999). Ten LAIV recipients shed virus; the latest viral shedding was detected 7 days after vaccination. Immunogenicity data were available for 52 subjects, or 26 in each group. TIV induced significantly higher postvaccination geometric mean titers against influenza A viruses (P <. 001), greater seroprotection against influenza A/H1N1 (P =. 01), and greater seroconversion against A/H3N2 (P =. 004), compared with LAIV. No differences after vaccination were observed against influenza B viruses.Conclusions.As expected, serum antibody response against influenza A strains were greater with TIV than with LAIV in children with cancer. Both vaccines were well tolerated, and prolonged viral shedding after LAIV was not detected.",
author = "Silvana Carr and Allison, {Kim J.} and {Van De Velde}, {Lee Ann} and Kelly Zhang and English, {Elizabeth Y.} and Amy Iverson and Daw, {Najat C.} and Scott Howard and Fariba Navid and Carlos Rodriguez-Galindo and Jie Yang and Adderson, {Elisabeth E.} and Jonathan Mccullers and Flynn, {Patricia M.}",
year = "2011",
month = "11",
day = "15",
doi = "10.1093/infdis/jir561",
language = "English (US)",
volume = "204",
pages = "1475--1482",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer

AU - Carr, Silvana

AU - Allison, Kim J.

AU - Van De Velde, Lee Ann

AU - Zhang, Kelly

AU - English, Elizabeth Y.

AU - Iverson, Amy

AU - Daw, Najat C.

AU - Howard, Scott

AU - Navid, Fariba

AU - Rodriguez-Galindo, Carlos

AU - Yang, Jie

AU - Adderson, Elisabeth E.

AU - Mccullers, Jonathan

AU - Flynn, Patricia M.

PY - 2011/11/15

Y1 - 2011/11/15

N2 - (See the editorial commentary by Halasa, on pages 1471-4.)Background.The safety and immunogenicity of live, attenuated influenza vaccine (LAIV) has not been compared to that of the standard trivalent inactivated vaccine (TIV) in children with cancer.Methods.Randomized study of LAIV versus TIV in children with cancer, age 2-21 years, vaccinated according to recommendations based on age and prior vaccination. Data on reactogenicity and other adverse events and blood and nasal swab samples were obtained following vaccination.Results.Fifty- five eligible subjects (mean age, 10.4 years) received vaccine (28 LAIV/27 TIV). Both vaccines were well tolerated. Rhinorrhea reported within 10 days of vaccination was similar in both groups (36% LAIV vs 33% TIV, P >. 999). Ten LAIV recipients shed virus; the latest viral shedding was detected 7 days after vaccination. Immunogenicity data were available for 52 subjects, or 26 in each group. TIV induced significantly higher postvaccination geometric mean titers against influenza A viruses (P <. 001), greater seroprotection against influenza A/H1N1 (P =. 01), and greater seroconversion against A/H3N2 (P =. 004), compared with LAIV. No differences after vaccination were observed against influenza B viruses.Conclusions.As expected, serum antibody response against influenza A strains were greater with TIV than with LAIV in children with cancer. Both vaccines were well tolerated, and prolonged viral shedding after LAIV was not detected.

AB - (See the editorial commentary by Halasa, on pages 1471-4.)Background.The safety and immunogenicity of live, attenuated influenza vaccine (LAIV) has not been compared to that of the standard trivalent inactivated vaccine (TIV) in children with cancer.Methods.Randomized study of LAIV versus TIV in children with cancer, age 2-21 years, vaccinated according to recommendations based on age and prior vaccination. Data on reactogenicity and other adverse events and blood and nasal swab samples were obtained following vaccination.Results.Fifty- five eligible subjects (mean age, 10.4 years) received vaccine (28 LAIV/27 TIV). Both vaccines were well tolerated. Rhinorrhea reported within 10 days of vaccination was similar in both groups (36% LAIV vs 33% TIV, P >. 999). Ten LAIV recipients shed virus; the latest viral shedding was detected 7 days after vaccination. Immunogenicity data were available for 52 subjects, or 26 in each group. TIV induced significantly higher postvaccination geometric mean titers against influenza A viruses (P <. 001), greater seroprotection against influenza A/H1N1 (P =. 01), and greater seroconversion against A/H3N2 (P =. 004), compared with LAIV. No differences after vaccination were observed against influenza B viruses.Conclusions.As expected, serum antibody response against influenza A strains were greater with TIV than with LAIV in children with cancer. Both vaccines were well tolerated, and prolonged viral shedding after LAIV was not detected.

UR - http://www.scopus.com/inward/record.url?scp=80054734187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054734187&partnerID=8YFLogxK

U2 - 10.1093/infdis/jir561

DO - 10.1093/infdis/jir561

M3 - Article

C2 - 21949042

AN - SCOPUS:80054734187

VL - 204

SP - 1475

EP - 1482

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 10

ER -